Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intracranial Aneurysm | 13 | 2020 | 370 | 3.130 |
Why?
|
| Aneurysm, Ruptured | 5 | 2020 | 76 | 1.680 |
Why?
|
| Cerebral Revascularization | 4 | 2021 | 30 | 1.590 |
Why?
|
| Lymphoma | 2 | 2020 | 104 | 1.190 |
Why?
|
| Endovascular Procedures | 5 | 2020 | 600 | 1.070 |
Why?
|
| Neuroma, Acoustic | 2 | 2019 | 13 | 1.030 |
Why?
|
| Brain Injuries | 5 | 2014 | 140 | 0.980 |
Why?
|
| Receptor, Cannabinoid, CB2 | 3 | 2014 | 10 | 0.920 |
Why?
|
| Encephalocele | 1 | 2021 | 15 | 0.720 |
Why?
|
| Arteriovenous Fistula | 2 | 2019 | 40 | 0.700 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 346 | 0.620 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2019 | 2 | 0.610 |
Why?
|
| Subarachnoid Hemorrhage | 3 | 2020 | 108 | 0.600 |
Why?
|
| Embolization, Therapeutic | 4 | 2019 | 323 | 0.600 |
Why?
|
| Cerebellopontine Angle | 2 | 2019 | 8 | 0.570 |
Why?
|
| Pons | 1 | 2018 | 15 | 0.570 |
Why?
|
| Spinal Cord Diseases | 2 | 2019 | 41 | 0.560 |
Why?
|
| Neurosurgical Procedures | 2 | 2019 | 99 | 0.550 |
Why?
|
| Cerebral Arteries | 1 | 2017 | 40 | 0.540 |
Why?
|
| Hemorrhage | 1 | 2019 | 265 | 0.540 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 188 | 0.530 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2018 | 80 | 0.530 |
Why?
|
| Neuroprotective Agents | 2 | 2019 | 75 | 0.510 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 457 | 0.510 |
Why?
|
| Aneurysm | 1 | 2016 | 58 | 0.490 |
Why?
|
| Cerebrovascular Circulation | 2 | 2014 | 181 | 0.480 |
Why?
|
| Anisoles | 2 | 2012 | 3 | 0.480 |
Why?
|
| Blood-Brain Barrier | 2 | 2014 | 85 | 0.470 |
Why?
|
| Stents | 3 | 2019 | 488 | 0.470 |
Why?
|
| Craniotomy | 2 | 2019 | 20 | 0.460 |
Why?
|
| Brain Neoplasms | 2 | 2019 | 311 | 0.450 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2014 | 8 | 0.450 |
Why?
|
| Cannabinoid Receptor Antagonists | 1 | 2014 | 4 | 0.450 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2014 | 8 | 0.450 |
Why?
|
| Sex Characteristics | 1 | 2016 | 201 | 0.440 |
Why?
|
| Spondylosis | 1 | 2014 | 26 | 0.410 |
Why?
|
| Gene Deletion | 1 | 2014 | 310 | 0.410 |
Why?
|
| Humans | 29 | 2021 | 63527 | 0.390 |
Why?
|
| Nerve Degeneration | 1 | 2012 | 72 | 0.370 |
Why?
|
| Vascular Surgical Procedures | 1 | 2014 | 243 | 0.360 |
Why?
|
| Perfusion Imaging | 1 | 2011 | 20 | 0.350 |
Why?
|
| Thrombolytic Therapy | 1 | 2011 | 192 | 0.320 |
Why?
|
| Treatment Outcome | 9 | 2020 | 5627 | 0.310 |
Why?
|
| Male | 16 | 2020 | 29931 | 0.290 |
Why?
|
| Patient Selection | 1 | 2011 | 487 | 0.290 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 1641 | 0.260 |
Why?
|
| Brain Ischemia | 1 | 2011 | 421 | 0.260 |
Why?
|
| Methemoglobin | 1 | 2006 | 5 | 0.250 |
Why?
|
| Adult | 8 | 2020 | 16895 | 0.240 |
Why?
|
| Retrospective Studies | 8 | 2021 | 6619 | 0.230 |
Why?
|
| Blood Transfusion | 1 | 2006 | 161 | 0.230 |
Why?
|
| Headache | 2 | 2017 | 58 | 0.230 |
Why?
|
| Moyamoya Disease | 2 | 2021 | 12 | 0.210 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2020 | 48 | 0.200 |
Why?
|
| Cerebral Angiography | 3 | 2019 | 294 | 0.190 |
Why?
|
| Cranial Fossa, Middle | 1 | 2021 | 1 | 0.180 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2021 | 14 | 0.180 |
Why?
|
| Mice, Inbred C57BL | 5 | 2019 | 3401 | 0.170 |
Why?
|
| Printing, Three-Dimensional | 1 | 2020 | 38 | 0.160 |
Why?
|
| Self Expandable Metallic Stents | 1 | 2020 | 33 | 0.160 |
Why?
|
| Eye | 1 | 2020 | 54 | 0.160 |
Why?
|
| Carotid Artery, Internal | 2 | 2019 | 68 | 0.160 |
Why?
|
| Surgical Instruments | 1 | 2020 | 43 | 0.160 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2019 | 6 | 0.160 |
Why?
|
| Radial Artery | 1 | 2020 | 54 | 0.150 |
Why?
|
| Cauda Equina | 1 | 2019 | 7 | 0.150 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2020 | 61 | 0.150 |
Why?
|
| Dimethyl Fumarate | 1 | 2019 | 8 | 0.150 |
Why?
|
| Femoral Artery | 1 | 2020 | 99 | 0.150 |
Why?
|
| Hemodynamics | 1 | 2020 | 248 | 0.150 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2019 | 30 | 0.150 |
Why?
|
| Female | 10 | 2020 | 32939 | 0.150 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 182 | 0.150 |
Why?
|
| Aneurysm, False | 1 | 2019 | 50 | 0.140 |
Why?
|
| Glasgow Outcome Scale | 2 | 2020 | 17 | 0.140 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2016 | 1 | 0.130 |
Why?
|
| Carotid Artery, External | 1 | 2016 | 2 | 0.130 |
Why?
|
| Anesthetics, Dissociative | 1 | 2016 | 7 | 0.130 |
Why?
|
| Registries | 2 | 2020 | 872 | 0.130 |
Why?
|
| Ketamine | 1 | 2016 | 38 | 0.120 |
Why?
|
| Disease Management | 1 | 2018 | 232 | 0.120 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 980 | 0.120 |
Why?
|
| Mice | 6 | 2019 | 10863 | 0.120 |
Why?
|
| Cyclohexanols | 2 | 2012 | 17 | 0.120 |
Why?
|
| Postoperative Complications | 2 | 2020 | 1278 | 0.110 |
Why?
|
| Aged | 5 | 2020 | 14451 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2012 | 2026 | 0.110 |
Why?
|
| Spinal Injuries | 1 | 2014 | 12 | 0.110 |
Why?
|
| Random Allocation | 1 | 2014 | 199 | 0.110 |
Why?
|
| Inflammation Mediators | 2 | 2015 | 177 | 0.110 |
Why?
|
| Vascular Diseases | 1 | 2015 | 81 | 0.110 |
Why?
|
| Dissection | 1 | 2014 | 48 | 0.100 |
Why?
|
| Middle Aged | 6 | 2020 | 17656 | 0.100 |
Why?
|
| Rotarod Performance Test | 1 | 2012 | 3 | 0.100 |
Why?
|
| Exploratory Behavior | 1 | 2012 | 37 | 0.090 |
Why?
|
| Hyperalgesia | 1 | 2012 | 15 | 0.090 |
Why?
|
| Databases, Factual | 2 | 2014 | 847 | 0.090 |
Why?
|
| Ticlopidine | 1 | 2012 | 49 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 98 | 0.090 |
Why?
|
| Neuropeptides | 1 | 2012 | 81 | 0.090 |
Why?
|
| Animals | 6 | 2019 | 20715 | 0.090 |
Why?
|
| Incidence | 2 | 2014 | 1372 | 0.090 |
Why?
|
| Cannabinoid Receptor Modulators | 1 | 2011 | 8 | 0.090 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2012 | 113 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2020 | 2571 | 0.090 |
Why?
|
| Inflammation | 2 | 2015 | 1146 | 0.080 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2012 | 211 | 0.080 |
Why?
|
| Comorbidity | 1 | 2014 | 1114 | 0.080 |
Why?
|
| Macrophages | 2 | 2015 | 1041 | 0.080 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2012 | 228 | 0.080 |
Why?
|
| Mice, Knockout | 1 | 2014 | 2113 | 0.080 |
Why?
|
| Neurons | 2 | 2012 | 923 | 0.080 |
Why?
|
| Microglia | 1 | 2012 | 242 | 0.080 |
Why?
|
| Young Adult | 2 | 2019 | 4714 | 0.070 |
Why?
|
| Color | 1 | 2006 | 25 | 0.060 |
Why?
|
| Hemolysis | 1 | 2006 | 40 | 0.060 |
Why?
|
| Hyperlipidemias | 1 | 2006 | 35 | 0.060 |
Why?
|
| Risk Factors | 2 | 2015 | 5282 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 2184 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 5468 | 0.050 |
Why?
|
| Temporal Arteries | 1 | 2021 | 5 | 0.050 |
Why?
|
| Middle Cerebral Artery | 1 | 2021 | 50 | 0.040 |
Why?
|
| Cadaver | 1 | 2021 | 128 | 0.040 |
Why?
|
| Decision Trees | 1 | 2020 | 51 | 0.040 |
Why?
|
| Catheterization, Peripheral | 1 | 2020 | 49 | 0.040 |
Why?
|
| Neuroendoscopy | 1 | 2019 | 1 | 0.040 |
Why?
|
| Thoracic Vertebrae | 1 | 2019 | 35 | 0.040 |
Why?
|
| Hemorheology | 1 | 2019 | 6 | 0.040 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 28 | 0.040 |
Why?
|
| Carotid Artery Diseases | 1 | 2019 | 61 | 0.040 |
Why?
|
| Equipment Design | 1 | 2019 | 357 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2019 | 153 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2019 | 297 | 0.030 |
Why?
|
| Antioxidants | 1 | 2019 | 252 | 0.030 |
Why?
|
| Adolescent | 2 | 2019 | 6259 | 0.030 |
Why?
|
| Urine | 1 | 2016 | 45 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 2016 | 115 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 92 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2015 | 178 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 2196 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2015 | 139 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2015 | 202 | 0.030 |
Why?
|
| Apoptosis | 1 | 2019 | 1080 | 0.030 |
Why?
|
| Balloon Occlusion | 1 | 2013 | 9 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 172 | 0.030 |
Why?
|
| Time Factors | 1 | 2020 | 3708 | 0.020 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2012 | 11 | 0.020 |
Why?
|
| Somatosensory Cortex | 1 | 2012 | 20 | 0.020 |
Why?
|
| Substance P | 1 | 2012 | 38 | 0.020 |
Why?
|
| Nociception | 1 | 2012 | 10 | 0.020 |
Why?
|
| Brain Stem | 1 | 2012 | 28 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 572 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2015 | 525 | 0.020 |
Why?
|
| Resorcinols | 1 | 2011 | 5 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 973 | 0.020 |
Why?
|
| Brain | 1 | 2020 | 1556 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 455 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 1259 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 897 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2015 | 3033 | 0.010 |
Why?
|